Two antibodies that block PD-1, pembrolizumab (Keytruda) and nivolumab (OPDIVO), have been approved to treat advanced or inoperable melanoma and the clinical responses are encouraging [25, 26]. The gene discussed is PDCD1; the disease is melanoma.